Arietis Corp. is a Boston-based biotechnology company focused on the discovery and development of novel antimicrobial agents. Our drug discovery pipeline focuses on sterilizing antibiotics that target Staphylococcus aureus, a leading cause of nosocomial and community acquired infections, and Helicobacter pylori, a cause of gastric ulcers and cancer. A newer discovery platform involves using synthetic biology to manipulate the human gut microbiome to improve human health and cure disease.
Pathogenic bacteria continually develop and spread resistance, yet the antibacterial armamentarium is increasingly limited. Founded in 2006, Arietis bridges an important gap in antimicrobial drug discovery and technology development. Arietis has forged productive alliances and partnerships within the biotechnology community as we advance our capacity to develop effective drug products. Arietis is committed to building value for its partners and shareholders, and we are well positioned to capitalize on the growing antimicrobial market. We are committed to providing innovative solutions for the problem of persistent infection, thereby decreasing the overall burden on healthcare worldwide.
The company was created based on technology invented by its founder, Professor Kim Lewis, Director of the Antimicrobial Center at Northeastern University, for which the company has obtained exclusive, world-wide licenses.